Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000708 | 1.00 | PAOX (0.34) | PAOXMC4RALDH1A1MEN1RAD52 | |
| SCHEMBL14477672 | 0.80 | SIGMAR1 (0.43) | ALDH1A1KMT2ASIGMAR1LMNATSHR | |
| SCHEMBL5946047 | 0.80 | ALDH1A1 (0.37) | PAOXALDH1A1MEN1RAD52KMT2A | |
| SCHEMBL10657199 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2ALMNATSHR | |
| SCHEMBL28132579 | 0.78 | — | — | |
| SCHEMBL5294936 | 0.78 | — | — | |
| SCHEMBL14210004 | 0.78 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL14258570 | 0.77 | MC4R (0.32) | PAOXMC4RSIGMAR1LMNAKDM4E | |
| SCHEMBL10000696 | 0.77 | DAO (0.35) | ALDH1A1SIGMAR1KDM4ETDP1 | |
| SCHEMBL5858594 | 0.77 | PAOX (0.43) | PAOXALDH1A1MEN1RAD52KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113552241-A | Method for determining residual content of 4-methylpiperazine-1-formate genotoxic impurities in zopiclone | 江苏天士力帝益药业有限公司 | 2021-10-26 | — | — | CN | claimed |
| WO-2024145638-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING TIRZEPATIDE | ELI LILLY AND COMPANY (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024077149-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | ELI LILLY AND COMPANY (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-114763342-A | Synthesis method of high-purity 4-methylpiperazine-1-formic ether | 江苏天士力帝益药业有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-113552241-A | Method for determining residual content of 4-methylpiperazine-1-formate genotoxic impurities in zopiclone | 江苏天士力帝益药业有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-113552241-A | Method for determining residual content of 4-methylpiperazine-1-formate genotoxic impurities in zopiclone | 江苏天士力帝益药业有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-1542718-B1 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION | XIE DONG (US) | 2015-11-11 | — | — | EP | disclosed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-20140187476-A1 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION | BAOBAB PHARMACEUTICALS LIMITED (HK) | 2014-07-03 | — | — | US | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| WO-2002085929-A1 | PROCESS FOR PREPARING LIPID II | ELI LILLY AND COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002066511-A2 | LONG LASTING GLUCAGON-LIKE PEPTIDE 2 (GLP-2) FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS | CONJUCHEM INC. (CA) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002062844-A2 | LONG LASTING GROWTH HORMONE RELEASING FACTOR DERIVATIVES | CONJUCHEM INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002018369-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001079268-A2 | A GLYCOPEPTIDE AND PREPARATION THEREOF | ELI LILLY AND COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001079242-A2 | PROCESS FOR PREPARING LIPID II AND DERIVATIVES THEREOF | ELI LILLY AND COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001079267-A2 | A GLYCOPEPTIDE AND PREPARATION THEREOF | ELI LILLY AND COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001058933-A2 | SELECTIVE N-ACYLATION OF A82846 GLYCOPEPTIDE ANALOGS | ELI LILLY AND COMPANY (US) | 2001-08-16 | — | — | WO | disclosed |
| US-6248919-B1 | E.G., (2S)-2-(((5-((BUTYL(2-CYCLOHEXYLETHYL)AMINO)METHYL) -2'-METHYL(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-4-(METHYLSULFAN YL)BUTANOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR PRODRUG THEREOF. | ABBOTT LABORATORIES | 2001-06-19 | — | — | US | disclosed |
| US-4093812-A | MICROBIOCIDES, DISINFECTANTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187476-A1 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION | VIP, HM13, BST2 | PAOX 4868/4885MC4R 4143/4885ALDH1A1 4875/4885 |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | PAOX 3435/4885MC4R 4613/4885ALDH1A1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.